Sitagliptin (Januvia®) Biocatalytic Process
Type 2 Diabetes
CommercialActive
Key Facts
About Codexis
Founded in 2002, Codexis has pioneered the use of engineered enzymes for pharmaceutical manufacturing, with a proven track record including the scale-up of an enzyme for Pfizer's Paxlovid. The company has strategically expanded into RNA manufacturing, offering a full enzymatic synthesis platform for oligonucleotides like siRNA. Codexis operates as a partner-driven business, providing custom enzyme solutions and manufacturing services to accelerate and de-risk therapeutic development for its clients.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Eli Lilly | Approved |
| Orforglipron | Eli Lilly | Phase 3 |
| Trulicity (dulaglutide) | Eli Lilly | Approved |
| Forxiga | AstraZeneca | Approved |
| siRNA GalXC-GYS2 | Novo Nordisk | Phase 1 |
| Amylin/semaglutide combination | Novo Nordisk | Phase 3 |
| Lipaglyn | Zydus Lifesciences | Approved |
| LBS-009 | Belite Bio | Preclinical |
| Jentadueto (Linagliptin/Metformin) | Yuhan | Approved |
| Nesina (Alogliptin) | Yuhan | Approved |
| Metformin & Combinations | Ipca Laboratories | Commercial |
| GSBR-1290 | Structure Therapeutics | Phase 2 |